Table 1 The characteristics of included studies
Study | Year | Country | Patients (n) | Age (year) | Gender | Symptom duration (months) | Side of involvement | Study design | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ESWT | US | ESWT | US | ESWT | US | ESWT | US | ESWT | US | ||||||||
| Â | Â | Â | Â | Â | Â | Â | Male | Female | Male | Female | Â | Â | Left | Right | Left | Right | Â |
Gunduz | 2012 | Turkey | 20 | 19 | 44.9 ± 9.9 | 43.6 ± 9.1 | 8 | 12 | 5 | 14 | 30 (1–90) | 30 (7–90) | 5 | 15 | 4 | 15 | RCT |
Kubot | 2017 | Poland | 30 | 30 | 47.6 ± 7.66 | 43.9 ± 9.44 | 8 | 22 | 17 | 13 | > 2 | > 2 | – | – | – | – | RCT |
Pawel | 2015 | Poland | 25 | 25 | 47.9 ± 4.4 | 49.0 ± 4.5 | – | – | – | – | 14.9 ± 2.1 | 15.1 ± 1.9 | 0 | 25 | 0 | 25 | RCT |
Yalvac | 2018 | Turkey | 20 | 24 | 43.75 ± 4.52 | 46.04 ± 9.24 | 5 | 15 | 8 | 16 | 7.9 ± 3.3 | 8.2 ± 3.6 | 3 | 17 | 4 | 20 | RCT |
Soheir | 2013 | Egypt | 20 | 20 | 38.4 ± 3.67 | 38.25 ± 4.19 | 12 | 8 | 12 | 8 | >10 | >10 | 15 | 4 | 17 | 4 | RCT |